– July 1, 2013
July 1, 2013
View Issues
-
Phase 2 Study of Erlotinib Combined with Adjuvant Chemoradiation and Chemotherapy in Patients with Resectable Pancreatic Cancer
In a prospective Phase 2 study, 48 patients with resected pancreatic ductal adenocarcinoma were treated with erlotinib (100 mg daily) and capecitabine (800 mg/m2 twice daily Monday-Friday) concurrently with intensity-modulated radiation therapy followed by four cycles of adjuvant gemcitabine (1000 mg/m2 on days 1, 8, and 15 every 28 days) and erlotinib (100 mg daily). -
Bevacizumab-Docetaxel-Carboplatin Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
In a single-arm, multicenter, Phase 2 trial, bevacizumab in combination with docetaxel and carboplatin achieved a pathological complete response in 19 of 45 patients with stage II/III triple-negative breast cancer. Forty-four of the 45 patients completed the planned six cycles and toxicity was manageable. One patient had delayed wound healing as a subsequent surgical complication. Thus, bevacizumab may provide significant improvement in neoadjuvant strategies for triple-negative breast cancer and further investigation is warranted. -
Prostate Cancer: Influence of Screening and Intervention on Mortality
Two recent reports provide supportive evidence for current strategies in the management of prostate cancer. The first, from Finland, is a report of the marginal value of PSA screening in terms of long-term prostate cancer survival. And, from a cooperative observational cohort in the United States, there is suggestive evidence that radical prostatectomy provides a somewhat more favorable survival outcome when compared to external beam radiotherapy. -
Qigong Reduces Depression in Women with Breast Cancer Receiving Radiotherapy
Ninety-six women with breast cancer undergoing radiotherapy during a 5- to 6-week interval were randomized to either a qigong group or a wait-list control group. The results indicate that the women in the qigong group had clinically significantly less depressive symptoms and better quality of life than the control group. -
Pharmacology Watch: Is Naproxen the Safest NSAID for the Heart?
NSAIDs and cardiovascular risk; new antithrombotic guidelines; warfarin during surgery; Pfizer selling Viagra online; azithromycin and cardiovascular risk; and FDA actions. -
Clinical Briefs in Primary Care Supplement